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Abstract: A full understanding of the immune response to astrovirus (AstV) infection is required to
treat and control AstV-induced gastroenteritis. Relative contributions of each arm of the immune
system in restricting AstV infection remain unknown. In this study, two novel subunit AstV vaccines
derived from capsid protein (CP) of mink AstV (MAstV) such as CP∆N (spanning amino acids
161–775) and CP∆C (spanning amino acids 1–621) were evaluated. Their immunogenicity and cytokine
production in mice, as well as protective efficacy in mink litters via maternal immunization, were
studied. Truncated CPs induced higher levels of serum anti-CP antibodies than CP, with the highest
level for CP∆N. No seronegativity was detected after booster immunization with either AstV CP
truncates in both mice and mink. All mink moms stayed seropositive during the entire 104-day study.
Furthermore, lymphoproliferation responses and Th1/Th2 cytokine induction of mice splenocytes
ex vivo re-stimulated by truncated CPs were significantly higher than those by CP, with the highest
level for CP∆N. Immunization of mink moms with truncated CPs could suppress virus shedding and
clinical signs in their litters during a 51-day study after challenge with a heterogeneous MAstV strain.
Collectively, AstV truncated CPs exhibit better parameters for protection than full-length CP.
Keywords: astrovirus; capsid protein; subunit vaccine; immunogenicity; infection
1. Introduction
Immunization against the viral pathogens causing gastrointestinal disorders is one of the most
important concerns in public and animal health. Development of viral vaccines has traditionally been
based on the use of attenuated live or inactivated viruses to induce protective immunity. This strategy
has generated both live attenuated and inactivated vaccines currently in use for different diseases.
Despite its efficacy, it has been difficult to extend this strategy to many viral pathogens because
attenuated strains are either difficult to produce or unreliable, and posing safety risks. Inactivated
vaccines, on the other hand, are safe but poorly immunogenic [1,2]. As a result, alternative vaccine
development strategies are being investigated and tested, such as recombinant DNA [3], protein-based
subunit vaccines [4], viral vector-based vaccines [5], vaccine generation by reverse genetics and codon
optimization approaches [6], and more recently mRNA vaccines [7]. Several efforts are aimed to
increase the immunogenicity and the safety of vaccines. In particular, subunit vaccines target specific
epitopes recognized for immunity and are safe since they do not involve replication of the viral
pathogen. However, these need to be combined with adjuvants to stimulate good immune responses
and often require repeated immunization. Vital aspects for subunit vaccines effectivity are that the right
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immunogens for protection are incorporated in the design, and that the vaccine stimulates the humoral
and, more importantly, the cellular arm of the immune response [4]. Therefore, the development
of vaccines based on recombinant proteins require strategies that target a strong Th1/Th2 immunity,
which is vital for protection and resistance to infections.
Astroviruses (AstVs) are positive-sense, single-stranded RNA, non-enveloped viruses that have
an icosahedral capsid, small size (28–30 nanometers in diameter), and star-like appearance in electron
microscopy (EM) [8]. The length of the genome is around 6.6 kb, and it contains three open reading
frames (ORFs). ORF1a and ORF1b encode precursors of the viral nonstructural proteins, while ORF2
encodes for the precursor of the viral structural protein [9–11]. It has been shown that the subgenomic
RNA of human astrovirus (HAstV), derived from ORF2, encodes a single, large viral structural capsid
protein (CP) [12]. This capsid polyprotein precursor contains around 775–785 amino acid (aa) residues,
depending on the virus strain, and has a molecular mass of 87–90 kilodalton (kDa) [13,14]. The AstV
CP is an external structural barrier that not only encapsidates nucleic acids but also interacts with
the host to define cell tropism, mediates cell entry, and triggers the host immune response [15]. As a
non-enveloped virus, AstV exhibits an intriguing feature in that its maturation requires extensive
proteolytic processing of the AstV CP both inside and outside the host cell [16].
AstV infection, as the second common cause of gastroenteritis after rotaviruses, begins by binding
to an unidentified receptor(s) on epithelial cells after fecal-oral transmission followed by entry via
endosomes [17]. In animals, AstVs cause gastrointestinal disease in mink [8], cattle [18], sheep [19],
pig [20], cats [21], dogs [22], and marine mammals [23]. In turkey and chicken, it also causes nephritis,
the runting-stunting syndrome, and gastrointestinal disease [24,25]. In addition, both classic and
novel AstVs were identified as the cause of unexpected central nervous system (CNS) infections in
human [26,27] and in animals such as mink [28], sheep [29], and cattle [30], highlighting that these
viruses may bypass the gastrointestinal tract and infect the brain and other organs.
Mink astrovirus (MAstV) is the causative agent of pre-weaning diarrhea syndrome in young
mink litters [8]. The syndrome is referred to “sticky”, “greasy”, or “wet” litters, and is characterized
by diarrhea and excessive secretion from cervical apocrine glands in mink litters usually at the age
of 1–4 weeks [8,11]. This results in the soiling of the neck and back, and a wavy appearance of fur.
Post mortem examination of litters dying from this syndrome reveals non-specific catarrhal enteritis
with hydropic epithelial cell degeneration, infiltration of mononuclear cells in the villous propria, and
hypersecretion of the apocrine neck glands [31]. The economic losses in Scandinavia alone amount
to 750 million Danish kroners (equal to 124 million US dollars), distributed in terms of mortality,
losses due to bad skin quality, associated labor, and costs for antibiotic treatment due to the misuse of
antibiotics, which also impacts on antibiotic resistance [32]. Thus, there is an urgent need for a vaccine
that protects mink against the disease and reduces economic losses to the mink farming and industry.
Due to difficulties vaccinating mink litters, eliciting high levels of maternal IgG antibodies, transferred
to litters upon vaccination of female adult minks, has been highlighted as a main criterion for such
a vaccine candidate. However, for human or birds, cellular and mucosal immunities could also be
considered for protection beside humoral immune response upon direct vaccination.
The difficulty to grow AstVs from different species has limited the possibility to produce
conventional vaccines based on live attenuated virus [33]. Therefore, molecular biology-based
methods are the current alternative to engineer subunit vaccines based on recombinant proteins or
oligonucleotides. The HAstV CP that contains the immunogenic domains has been expressed mostly for
functional studies [16,34,35]. Our previous work with a full-length CP of MAstV expressed in bacteria
has shown partial protection against the manifestation of clinical symptoms of pre-weaning diarrhea
syndrome in mink [36]. In an immunization trial with a full-length CP of the chicken AstV expressed
in baculovirus, partial protection was also reported [37]. In the present study, we compared the
immune responses to full-length, and N- and C-terminally truncated forms of MAstV CP. The antibody
response, proliferative ability, and induction of cytokines in splenocytes were determined following
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immunization of mice. We also evaluated maternal passive immunization in minks by investigating
virus shedding and clinical signs in litters after challenging with a heterologous MAstV strain.
2. Materials and Methods
2.1. Construction and Expression of MAstV Vaccine Candidates
The construction and expression of the full-length and truncated MAstV CP of strain DK5790 using
pDual-GC vector (Agilent Technologies, Santa Clara, CA, USA) have been described [36]. CP refers to
the full-length capsid protein (spanning amino acids (aa) 1–775 of CP); CP∆N refers to an N-terminal
truncated protein (spanning aa 161–775 of CP); CP∆C is a C-terminal truncated protein (spanning aa
1–621 of CP). The MAstV CPs were expressed in stably transfected fetal mink cells and were purified
by affinity in a nickel resin, as described in details in our previous study [36].
2.2. Immunogenicity Evaluation in Mice
Four groups, each containing eight Naval Medical Research Institute (NMRI) mice at the age of 4
weeks (Charles River Laboratories, Wilmington, MA, USA) were used in this study. The mice trial
(project number: 10/122) were carried out at the National Veterinary Institute of Sweden in accordance
with both institutional and Swedish National Committee for the protection of animals used for scientific
purposes’ guidelines (Ethical number: C236/8). Three groups were injected subcutaneously with
0.2 mL of a mixture of 5 µg of CP-, CP∆N-, or CP∆C-proteins in phosphate-buffered saline (PBS)
with 10 µg of AbISCO-100 adjuvant (Isconova, Uppsala, Sweden) per mouse. Mice in the sham
group (n = 8) were also injected with 0.2 mL of PBS containing 10 µg of AbISCO-100 adjuvant. Three
weeks after the first immunization, the mice received a second injection of AstV protein or control cell
lysate applied as before. Blood sera were collected three weeks after each immunization and stored
at −20 ◦C. We used an indirect enzyme-linked immunosorbent assay (ELISA) to measure humoral
immune response. Animals in each group were sacrificed three weeks after the second immunization.
Splenocytes were harvested, seeded in 96-well plates and re-stimulated with various concentrations
of the purified AstV CPs in order to measure proliferation activity and cytokine secretions to study
cellular immune responses.
2.3. Protective Efficacy Evaluation in Mink
Seventeen adult female wild type minks at the age of 1-year old were purchased from a MAstV-free
farm in Denmark and transported to the National Veterinary Institute, Technical University of Denmark,
where all mink experiments were carried out in accordance with both institutional and Danish Animal
Care and Ethics Committee’s national guidelines (Ethical number: 08/561-1534). All minks were first
tested for antibodies to MAstV, with negative results. Their polymerase chain reaction (PCR) results
also did not show any active AstV infection. The adult female minks then were injected subcutaneously
with 100 µg of CP∆N (n = 6), CP∆C (n = 6), or with pDual-GC-vector-transfected cell lysate as sham
(n = 5) combined with an equal amount of Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO, USA)
(Table 1). The immunization was repeated three weeks after. The 1-day-old litters (n = 89) born to
these immunized female moms were inoculated orally with a high dose of challenge MAstV Danish
strain DK7627 (107 virus genome copies). The author veterinarians recorded clinical symptoms in
the litters on a daily basis. Totally, 414 fecal samples were collected at different days post-challenge
throughout the observation period (51 days) and tested with a quantitative real-time RT-PCR (targeted
non-structural gene of MAstV, Threshold = 0.02, unpublished data) and one-step RT-PCR kits (Qiagen,
Hilden, Germany) for determination of virus shedding after challenge (Table 1).
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Table 1. Summarizing the data of various groups in the mink trial.
Group of Experiment No. of Adult FemaleMinks (%)
No. of Litters
(%)
No. of Samples Tested
by PCR (%)
Sham 1 5 (30) 16 (18) 87 (21)
CP∆N 2 -immunized 6 (35) 31 (35) 146 (35)
CP∆C 3 -immunized 6 (35) 42 (47) 181 (44)
Total 17 (100) 89 (100) 414 (100)
Note: 1 Sham refers to the control group injected with pDual-GC-vector-transfected cell lysate; 2 CP∆N refers to
an N-terminal truncated protein (spanning aa 161–775 of CP) of MAstV; 3 CP∆C refers to a C-terminal truncated
protein (spanning aa 1–621 of CP) of MAstV.
The challenge materials came from a farm that reported extensive MAstV infection and suffering
from shaking mink syndrome. To prepare the challenge materials, the fecal samples were first tested
for positive MAstV by a quantitative real-time PCR [36] and also EM (Figure 1). Sequencing results
showed the presence of a heterogeneous Danish strain DK7627 in the fecal samples compared to the
strain DK5790 that was used to design and prepare AstV CP subunit vaccine candidates. Using 0.2 µm
filters, the positive fecal samples were filtered to avoid bacterial and fungal contamination. These
filtered materials were further exploited as MAstV-positive fecal filtrate for challenging the litters born
to immunized moms during this experimental study.
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2.4. Indirect ELISA
To detect the anti-MAstV CP specific antibodies in serum samples of mice and minks, an indirect
ELISA was developed and used as previously described [36]. Briefly, a recombinant MAstV CP was
first expressed in BL-21 competent Escherichia coli cells, then lysed mechanically by sonication and
purified using HisTrap™ columns (GE Healthcare, Uppsala, Sweden) in nickel affinity chromatography.
The wells of high-binding ELISA plates (Nunc-Immuno™ Plates, Thermo Fisher Scientific, Waltham,
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MA, USA) were then coated with 100 ng/well of the purified recombinant MAstV CP diluted in
carbonate buffer (pH 9.6, Sigma Aldrich, St. Louis, MO, USA) and incubated overnight at 4 ◦C. Next,
the plates were washed three times with PBS-T (PBS with 0.05% Tween 20, Thermo Fisher Scientific,
Waltham, MA, USA) and blocked with 100 µL/well of blocking solution (PBS-T containing 5% of
skimmed milk) for 1 h. The plates were washed with PBS-T three times. One hundred microliters of
serum samples diluted 1:100 in blocking buffer were added to each well, and the plates were incubated
at 37 ◦C for 1 h. After washing with PBS-T, horseradish peroxidase-labeled mouse anti- mustelid
IgG secondary antibody (MyBioSource, San Diego, CA, USA) diluted 1:1600 in blocking buffer was
added, and the plates were incubated for another 1 h. After three washes as before, the substrate
solution (tetramethylbenzidine) was added; the reaction was stopped by adding 100 µL 1M sulfuric
acid (H2SO4) to each well. All incubation steps were performed at room temperature. The optical
density (OD) was measured at 450 nm in an ELISA microplate reader (Biocompare, San Francisco,
CA, USA). The experiment was done in duplicate. The mean OD for the antigen-negative wells was
subtracted from each result, and the OD for each sample was corrected to a positive serum with the
limit values of 2.0 OD in each run to generate a corrected optical density (COD) value. Serum samples
from pre-immune mink and mice were used as a negative control with a COD value of <0.6 and
<0.3, respectively.
2.5. Proliferation Assay
Spleens collected from the mice were processed for isolation of splenocytes three weeks after
the second immunization. The freshly isolated splenocytes’ suspensions were counted and plated
in 96-well cell culture plates at a density of 2 × 105 cells/well in Roswell Park Memorial Institute
(RPMI) and the medium supplemented with 5% of fetal calf serum, 0.2% of L-Glutamine, 100 Units/mL
of penicillin, 100 µg/mL of streptomycin, and 0.1% of 2-mercaptoethanol. After overnight incubation at
37 ◦C, the cells were stimulated with 1, 2, 4, and 8 µg/mL of the corresponding MAstV CPs, in triplicate
wells for each protein concentration. Cells from the sham mice were also stimulated in the same
manner. Following incubation for 48 h at 37 ◦C, 5% CO2, the plates were centrifuged at 1200 rpm
for 10 min, and the supernatants were removed and stored at −70 ◦C for determination of cytokines.
For evaluation of proliferation, 96-well cell culture plates containing cell suspension were prepared
and treated as before. Following incubation for 48 h at 37 ◦C, 5% CO2, the proliferation of specific cells
was assessed using a water-soluble tetrazolium salt (WST-1) rapid Cell Proliferation kit (Calbiochem,
San Diego, CA, USA). 10 µL of the WST-1 mixture, a colorimetric indicator of cell viability was added,
and absorbance at 450 nm was measured with a spectrophotometer reader 2 h later.
2.6. Cytokine Profiling
The collected culture supernatants of the ex vivo-stimulated splenocytes were analyzed in triplicate
using the mouse Th1/Th2 Cytokine Cytometric 6-plex Array Bead kit (Invitrogen, Carlsbad, CA, USA)
that detects Interferon gamma (IFN-γ) and Interleukins (IL2, IL-4, IL-5, IL-10, and IL-12), according to
the manufacturer’s protocol. Briefly, filter plates were pre-wetted, and 50 µL of coated bead suspension
was added to each well and washed twice in a Tecan device. The samples and standards (50 µL)
were then added in duplicate wells; the plates were sealed and shaken for 30 s at 1100 rpm and then
incubated for 1 h, shaken at 300 rpm. The plates were washed three times, and 25 µL of diluted detection
antibody was added to each well. The plates were shaken as before and then incubated for 30 min,
shaken at 300 rpm in the dark. After washing three times, 50 µL of 1× streptavidin-Phycoerythrin (PE)
was added to every well, and the plates were incubated for 10 min. The plates were washed again,
and the beads were resuspended in 125 µL of the resuspension buffer, mixed by brief vertexing, and
immediately read on the Luminex® 100/200™ System (R&D Systems, Minneapolis, MN, USA) using
xPONENT® software (Luminex Corporation, Austin, TX, USA).
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2.7. Statistical Analysis
The mean COD value and standard deviation (SD) of the T-cell proliferation test and the
cell-mediated Luminex results of each group of immunized and sham mice were analyzed by using
Student’s t-test (two-tailed distribution, two-sample unequal variance, Heteroscedastic) for differences
among groups. Indeed, ELISA results were analyzed statistically using two-way analysis of variance
(ANOVA) with replication test. The number of asterisks in figures show various significant differences
between the variables: * for p < 0.05, ** for p < 0.01, and *** for p < 0.001. Comparison of secreted
cytokine profiles measured by Luminex was performed using GraphPad Prism software version 4
(GraphPad Software, San Diego, CA, USA) and illustrated as heatmaps.
3. Results
3.1. Antibody Responses to MAstV CPs in Mice
Blood of mice immunized with CP, CP∆N, or CP∆C proteins and of sham mice (n = 8 per group)
were collected three weeks after the first and second immunizations (Figure 2A). The sera were
analyzed with an indirect ELISA for the detection of antibodies to MAstV CP. The antibody levels after
the first immunization were low and without difference between the immunized mice groups and
also between immunized and sham mice groups. After receiving the booster injection, the immunized
mice showed a significant increase in anti-MAstV CP antibody levels (p < 0.05) compared to the first
immunization. Interestingly, the antibody levels induced by CP∆N increased significantly (p < 0.001)
after the booster and were markedly higher (p < 0.01) than antibodies generated by the booster of CP
or CP∆C immunogens (Figure 2B). Although the antibody reactions to CP and CP∆C had similar mean
COD values both after the first and booster immunizations, their mean COD values after the booster
were significantly higher than sham (p < 0.05).
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The serum samples of mice were collected three weeks after each immunization and tested with an
indirect ELISA (Limit of detection (L.O.D) is the corrected optical density (COD) above 0.3). CP refers
to the full-length capsid protein (spanning amino acids (aa) 1–775 of CP) of MAstV; CP∆N refers to
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truncated protein (spanning aa 1–621 of CP) of MAstV; Sham refers to the control group injected with
pDual-GC-vector-transfected cell lysate. The mean value of each group (n = 8) of mice was calculated,
the COD value of each mouse is illustrated in the dot plot. Asterisks indicate the level of significant
difference between the mean value of either immunized or sham groups using two-way analysis of
variance (ANOVA) with replication test (* p < 0.05, ** p < 0.01 and *** p < 0.001). Bars represent the
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3.2. Proliferation Activity of Mice Splenocytes Immunized with MAstV CPs
The viability of splenocytes using WST-1 labeling mixture was measured, showing different effects
of various concentrations of MAstV CPs on splenocyte proliferation. Readings were indicative of
lymphocyte proliferation recorded in supernatants from stimulated splenocytes in immunized but
not in sham mice (Figure 3). Comparing to the sham group, the CP group did not induce splenocyte
proliferation at higher than 4 µg/mL concentrations of MAstV CP (Figure 3). In contrast, CP∆N
and CP∆C showed significant increases (p < 0.05) in proliferation ability in response to increased
concentration of these MAstV CPs (Figure 3B,C). Splenocytes from sham mice, when stimulated with
CP∆N or CP∆C, showed slightly higher proliferation at higher concentrations of these MAstV CPs
(Figure 3B,C). However, increasing the CP concentration decreased the proliferation of splenocytes
from sham mice too (Figure 3A).
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Figure 3. Proliferation as ay of mice splenocytes after e-stimulation with different concentrations of
the corresponding MAstV capsid proteins. The MAstV vac ine candidates (5 µg/mouse) combined
with an equal volume of AbISCO-10 adjuvant (10 µg/mouse) wer injected to NMRI mice (n = 8 per
group, 4 we ks old) twice with a thre -we k interval. Mice injected with pDual-GC-vector-transfected
cell lysate combined with adjuvant were also analyzed as ham (n = 8). Thre we ks after the second
immunization, the splenocytes ere r t fr ll ice groups: (A) CP-i munized (n = 8),
(B) CP∆N-i munized (n = 8), and (C) CP∆C-immunized (n 8). s l c t s re then purified,
cultivated ex vivo (2 × 105 cells/ ell), a sti late by exposing to different final concentrations
(1 µg, 2 µg, 4 g, an 8 g) of the correspon ing st CPs as described in Materials and Methods;
cell proliferation was measured in a WST-1 assay after 48 h of incubation. The splenocytes of the sham
group (n = 8) were also independently exposed to each of the three MAstV CPs. The data are mean
COD value readings of triplicate experiments. Asterisks indicate a significant difference at the given
protein concentration between immunized and sham mice tested by two-way ANOVA with replication
test (* p < 0.05). Error bars represent standard deviation (SD).
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3.3. Cytokine Profiling of MAstV CPs-Immunized Mice
Next, we investigated the capacity of different generated MAstV CPs to induce specific Th1
and Th2 responses. The culture supernatants from stimulated splenocytes with 2 and 4 µg/mL
concentrations of MAstV CPs were assessed for secreted cytokines using the mouse Th1/Th2 Cytokine
Cytometric 6-plex Array Bead kit (Invitrogen, Carlsbad, CA, USA) that measures IFN-γ, IL-2, IL-4, IL-5,
IL-10, and IL-12. The results are displayed as heatmaps (Figure 4A,B). For IL-2, a significant readout
was found in mice immunized with all three proteins. Indeed, the readouts in mice immunized with
truncated CPs were found higher than full-length CP and were the highest in the CP∆N-immunized
mice group when exposed to a higher (4 µg/mL) concentration of this immunogen (Supplementary
Figure S1A). For IL-4, the measured values were, in general, low with a minor difference between CP
and the two CP truncates (data not shown). IL-5 and IL-10 responses showed a similar pattern to
IL-2, with higher and significant stimulation induced in mice immunized with CP∆N (Supplementary
Figure S1B,C). Furthermore, mice immunized with CP did not show any difference between IL-5
and IL-10 responses (Supplementary Figure S1B,C). For IL-12, there were no differences between the
readings of immunized and sham mice showing that there is no induction of this cytokine by any
of MAstV CPs (data not shown). No significant changes in cytokine levels were observed in sham
mice for the investigated interleukins (Figure 4). For IFN-γ, significantly super high levels of cytokine
were induced in immunized mice when stimulated with CP∆N (p < 0.001); four folds at 2 µg/mL and
eight folds at 4 µg/mL concentration of CP∆N (Supplementary Figure S1D). Also, readings of IFN-γ
from CP∆C (p < 0.05), though not as high as CP∆N were higher than those from CP at increasing
concentrations of this immunogen: One-fold at 2 µg/mL and three folds at 4 µg/mL concentration of
CP∆C (Supplementary Figure S1D). Interestingly, naïve mice in the sham group when stimulated with
the different concentrations of only CP∆N and CP∆C also showed a higher level of expression for
IFN-γ response (Figure 4), showing the capability of the two AstV CP truncates in immunogenicity in
naïve mice.
Though inducing a low level of antibodies, the CP∆C is endowed with better capacity for mounting
a recall response by means of strong cellular immunity, compared to the full-length CP. The CP∆N
protein of AstV combines both the ability to induce high levels of antibodies (humoral response) with
the capacity to stimulate cytokine production (cellular response) thereby stimulating both arms of
the immune response. In general, the production of cytokines increased with the amount of MAstV
CPs used in the re-stimulation of splenocytes. Altogether, the results showed a poor ability of CP to
stimulate cellular responses based on the measured cytokines. On the other hand, the findings also
reveal differences in the degree of cytokine induction between CP∆N and CP∆C, albeit the fact that
they both stimulate cellular responses. The practical significance of this circumstance in full protection
was also evaluated in challenge experiments in mink litters.
Maternal passive immunization with truncated MAstV CPs was done in mink. A total of 85
serum samples were taken from MAstV CPs-immunized female adult minks (n = 17) on five occasions
during a 104-day experiment (Figure 5A). Using ELISA, the levels of anti-MAstV CP antibody in
serum samples were measured. The ELISA results of each MAstV vaccine candidate are shown in
Figure 5B. Both CP∆N- and CP∆C-vaccinated groups generated significantly higher levels of antibodies
after the first and second immunization, compared to the sham group (p < 0.01), with a highest
(p < 0.001) anti-MAstV CP antibody titer three weeks after the second immunization (day 39; Figure 5B).
Furthermore, though a slight decrease, these vaccinated adult females showed a significantly higher
level of anti-MAstV CP antibody (p < 0.01) than the naïve sham group (Figure 5B) during the entire
trial. The antibody levels, generated after the first immunization with CP∆C-vaccinated candidates,
were significantly higher than the CP∆N-vaccinated group (p < 0.01) as measured on day 17 (Figure 5B).
However, this level after the second immunization with CP∆N was measured slightly higher than that
of the CP∆C-vaccine candidate (Figure 5B) as measured on day 39.
Vaccines 2019, 7, 79 10 of 20
Vaccines 2019, 7, x FOR PEER REVIEW 9 of 21 
 
3.3. Cytokine Profiling of MAstV CPs-Immunized Mice 
Next, we investigated the capacity of different generated MAstV CPs to induce specific Th1 and 
Th2 responses. The culture supernatants from stimulated splenocytes with 2 and 4 µg/mL 
concentrations of MAstV CPs were assessed for secreted cytokines using the mouse Th1/Th2 
Cytokine Cytometric 6-plex Array Bead kit (Invitrogen, Carlsbad, CA, USA) that measures IFN-γ, IL-
2, IL-4, IL-5, IL-10, and IL-12. The results are displayed as heatmaps (Figure 4A,B). For IL-2, a 
significant readout was found in mice immunized with all three proteins. Indeed, the readouts in 
mice immunized with truncated CPs were found higher than full-length CP and were the highest in 
the CPΔN-immunized mice group when exposed to a higher (4 µg/mL) concentration of this 
immunogen (Supplementary Figure S1A). For IL-4, the measured values were, in general, low with 
a minor difference between CP and the two CP truncates (data not shown). IL-5 and IL-10 responses 
showed a similar pattern to IL-2, with higher and significant stimulation induced in mice immunized 
with CPΔN (Supplementary Figure S1B,C). Furthermore, mice immunized with CP did not show any 
difference between IL-5 and IL-10 responses (Supplementary Figure S1B,C). For IL-12, there were no 
differences between the readings of immunized and sham mice showing that there is no induction of 
this cytokine by any of MAstV CPs (data not shown). No significant changes in cytokine levels were 
observed in sham mice for the investigated interleukins (Figure 4). For IFN-γ, significantly super high 
levels of cytokine were induced in immunized mice when stimulated with CPΔN (p < 0.001); four 
folds at 2 µg/mL and eight folds at 4 µg/mL concentration of CPΔN (Supplementary Figure S1D). 
Also, readings of IFN-γ from CPΔC (p < 0.05), though not as high as CPΔN were higher than those 
from CP at increasing concentrations of this immunogen: One-fold at 2 µg/mL and three folds at 4 
µg/mL concentration of CPΔC (Supplementary Figure S1D). Interestingly, naïve mice in the sham 
group when stimulated with the different concentrations of only CPΔN and CPΔC also showed a 
higher level of expression for IFN-γ response (Figure 4), showing the capability of the two AstV CP 
truncates in immunogenicity in naïve mice. 
 
Figure 4. Heatmap of T-cell-mediated immune response to the corresponding MAstV CPs. The 
MAstV vaccine candidates (5 µg/mouse) combined with an equal volume of AbISCO-100 adjuvant 
(10 µg/mouse) were injected into NMRI mice (n = 8 per group, 4 weeks old) twice with a three-week 
interval. Mice injected with pDual-GC-vector-transfected cell lysate combined with adjuvant was also 
analyzed as a sham (n = 8). Three weeks after the second immunization, mice splenocytes were 
harvested from each group of mice: CP-immunized mice, CP∆N-immunized mice, and CP∆C-
immunized mice. Mice injected with pDual-GC-vector-transfected cell lysate combined with adjuvant 
was also analyzed as a sham (n = 8). The splenocytes of four mice per group were then extracted, 
washed, and cultivated ex vivo (2 × 105 cells/well) and stimulated by exposing to (A) 2 µg/mL and (B) 
4 µg/mL of the corresponding MAstV CPs as described in Materials and Methods. The culture 
supernatants from stimulated splenocytes were collected and assessed for secreted cytokines IL-2, IL-
5, IL-10, and IFN-γ by using a mouse Th1/Th2 Cytokine Cytometric 6-plex Array Bead kit 
(Invitrogen), Luminex® 100/200™ System and xPONENT® software (Luminex Corporation, Austin, 
TX, USA). The splenocytes of the sham group (n = 8) were also independently exposed to each of the 
(A) (B) 
Figure 4. Heatmap of T-cell-mediated immune response to the corresponding MAstV CPs. The MAstV
vaccine candidates (5µg/mouse) co bined with an equal volume of AbISCO-100 adjuvant (10µg/mouse)
were injected into NMRI mice (n = 8 per group, 4 weeks old) twice with a three-week interval. Mice
injected with pDual-GC-vector-transfected cell lysate combined with adjuvant was also analyzed
as a sham (n = 8). Three weeks after the second immunization, mice splenocytes were harvested
from each group of mice: CP-i munized ice, CP∆N-immunized ice, an CP∆C-immunized
ice. Mice injected with pDual-GC-vector-transfected cell lysate combined with adjuvant was also
analyzed s sham (n = 8). The splenocyte of four mice per group were then extracted, washed, and
cultivated ex vivo (2 × 105 cells/well) and stimul ted by exposing to (A) 2 µg/mL and (B) 4 µg/mL
of the corresponding MAstV CPs as described in Materials and M thods. The culture sup rnatants
from stimulated splenocytes wer c llected and ass ssed for secreted cytokin s IL-2, IL-5, IL-10, and
IFN-γ by using a mouse Th1/Th2 Cytokin Cytometric 6-plex Array Bead kit (Invitrogen), Luminex®
100/200™ System a d xPONENT® software (Luminex Corporation, Austin, TX, USA). The splenocytes
of the sham group (n = 8) were also independently expos d to each of the three MA tV CPs. The data
are mean COD readings of duplicate experiments, illustrated as log 10 values in the heatmap.
After the challenge of the mink litters (on day 1 with 107 MAstV genome copies of a heterologous
strain), the clinical signs and virus shedding of their litters were investigated. The litters showed
clinical signs including poor body condition, skin redness, severe diarrhea, and black nails, although
the vaccinated groups showed milder severity of clinical signs compared to the sham group (Figure 6A).
Furthermore, the ratio of litters with either clinical signs of AstV infection declined among vaccinated
groups compared to the sham group (Figure 6A). Only 14.3% of litters (n = 42) in CP∆C and less than
half (48.4%) of litters (n = 31) in CP∆N groups showed poor body conditions. While more than half
(56.2%) of litters (n = 16) in the sham group showed severe diarrhea on days 7–14 post-challenge, only
around 38% of litters (12 out of 31) in CP∆N and (16 out of 42) in CP∆C groups showed mild to severe
diarrhea (Table 2). Greasy skin signs were observed in 68.7% (11 out of 16) of litters in the sham group,
while this main clinical sign of MAstV infection was observed only in 38.7% (12 out of 31) of litters in
CP∆N group and 45.2% (19 out of 42) of litters in CP∆C group. For black nail sign rates of MAstV
infection, the litters in CP∆N and CP∆C groups showed around 50% and 70% lower rates, respectively,
compared to those in the sham group (Table 2).
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astrovirus capsid protein (MAstV CP) vaccine candidates in adult mink oms. (A) The MAstV vaccine
candidates (100 µg/animal) combined with an equal amount of Freund’s adjuvant were injected into
female adult minks (n = 6 per group) twice with three weeks interval. The adult moms injected with
pDual-GC-vector-transfected cell lysates combined with adjuvant were also analyzed as a sham (n = 5).
On day (D) 1 after birth, the litters (n = 89) of these immunized and sham adult mink moms (n = 17)
were then challenged orally with 107/mL MAstV copies. As a follow-up, the fecal samples of their
newborn litters on test days 1, 3, 5, 7, 9, 16, 30, 45, 50, and 51 after birth were tested using real-time
PCR for detecting astrovirus shedding status. The clinical signs of litters were also monitored and
recorded by veterinarians every other day. (B) Serum samples of the adult moms were collected on
test days 1, 17, 39, 60, and 104 and tested with an indirect ELISA for measuring maternal antibody
production against MAstV (Limit of detection (L.O.D) is the corrected optical density (COD) above
0.6). CP∆N refers to an N-terminal truncated protein (spanning aa 161–775 of CP) of MAstV; CP∆C
refers to a C-terminal truncated protein (spanning aa 1–621 of CP) of MAstV; Sham refers to the control
group injected with pDual-GC-vector-transfected cell lysate. Asterisks indicate significant differences
at the given protein concentration between various immunized and sham adult mink moms tested by a
two-way ANOVA with replication test (* p < 0.01, ** p < 0.001). Error bars represent SD.
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(%) 
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Table 2. Summarizing the evaluated clinical sign observation of litters in mink trial.
Group of Experiment No. of
Litters (%)
Evaluated Clinical Signs in Litters
Greasy
Puppies
(%)
Poor Body
Condition
(%)
Skin
Redness
(%)
Severe
Diarrhea
(%)
Black
Nails
(%)
Sham 1 16 (18) 11 (68.7) 10 (62.5) 16 (100) 9 (56.2) 15 (90.4)
CP∆N 2 -immunized 31 (35) 12 (38.7) 15 (48.4) 18 (58.1) 12 (38.7) 13 (42)
CP∆C 3 -immunized 42 (47) 19 (45.2) 6 (14.3) 33 (78.6) 16 (38.1) 9 (21.4)
Note: 1 Sham refers to the control group injected with pDual-GC-vector-transfected cell lysate; 2 CP∆N refers to
an N ter inal truncated protein (spanning aa 161–775 of CP) of MAstV; 3 CP∆C refers to a C-terminal truncated
protein (spanning aa 1–621 of CP) of MAstV.
Totally, 414 fecal samples of all 89 litters (87 samples from the sham moms’ litters (n = 16), 146
from CP∆N-vaccinated moms’ litters (n = 31), and 181 from CP∆C-vaccinated moms’ litters (n = 42))
were c llected on nine occasions and tested by PCR for shedding MAstV detection during the 51-day
challenging experim nt in litters (Table 1). O the day of challenge (d y 1) and day 3, all litters
test d to fi d th a urate time tha MAstV shedding starts. To follow up all litters during this
experime t, two litters of each adult mom were teste using a real-time PCR on each samp ing occasion.
The rati of positive sampl s to the total number of tested li ter of each group on a sampling occasion
was calcula ed and presented as a percentage. The resul s showed that on day 7 post-challenge, the rate
f virus-shedding among the litters in both CP∆N- nd CP∆C-vaccinated mom groups significantly
declined (>40%) compared to that of the ham mom group (p < 0.05) (Figure 6B, Supplementary
Figure S2). This significantly lower rate (40%) of virus-shedding prolonged to day 9 just he
CP∆N-vaccinated moms’ litters, and stayed lower than those in CP∆C-vaccinated moms (by 30%) and
the sham moms (by 40%) groups. In this study, at the peak of virus shedding (day 16), when all (100%)
litters in the CP∆C-vaccinated moms group (n = 12), and sham moms groups (n = 8) were detected
positive, almost 20% of litters (n = 11) in the CP∆N-vaccinated moms group were found free from
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MAstV infection. Furthermore, the remaining sampled litters (6 out of 9) in the CP∆N group and most
of the sampled litters (9 out of 12) in CP∆C group on day 16 were detected with a lower rate (Ct value
> 30, corresponding to 103 RNA copies of MAstV) of MAstV shedding using a quantitative PCR [36]
compared to sham group in which all litters (8 out of 8) were detected with a high rate (Ct value < 20,
corresponding to 106 RNA copies of MAstV) of virus shedding in their fecal samples. Also, the period
of virus shedding in litters was recorded between 3–50 days post-challenge (Figure 6B, Supplementary
Figure S2). Collectively, the litters in both CP∆N- and CP∆C-vaccinated moms groups showed milder
rates of all investigated clinical signs and also lower rates of virus shedding post-challenge, with a
high dose of heterogeneous MAstV strain DK7627 (107 virus genome copies), when compared with the
litters in the sham moms group. This is also in correlation with a higher rate of MAstV seropositivity
of their mink moms immunized with CP truncates, compared to full-length CP and the sham group
(Table 3). This indicates the protective effect of maternal immunization with truncated-MAstV CPs
vaccine candidates. Indeed, anti-MAstV antibodies generated by this strategy could pass to litters
during and/or after gestation and could neutralize MAstV post-challenge.
Table 3. Seropositivity ratio of animal models 3 weeks after the first and second immunization during
in vivo trials.
Group of Experiment
Ratio of Seropositivity (%)
3 Weeks after First Immunization 3 Weeks after Second Immunization (Booster)
Mice Mink Mice Mink
Sham 1 0/8 (0) 0/5 (0) 0/8 (0) 0/5 (0)
CP 2 -immunized 0/8 (0) NT 3 5/8 (62.5) NT
CP∆N 4 -immunized 0/8 (0) 5/6 (83.3) 8/8 (100) 6/6 (100)
CP∆C 5 -immunized 0/8 (0) 5/6 (83.3) 7/8 (87.5) 6/6 (100)
Note: 1 Sham refers to the control group injected with pDual-GC-vector-transfected cell lysate; 2 CP refers to the
full-length capsid protein (spanning amino acids (aa) 1–775 of CP) of MAstV; 3 NT—Not tested; 4 CP∆N refers to
an N-terminal truncated protein (spanning aa 161–775 of CP) of MAstV; 5 CP∆C refers to a C-terminal truncated
protein (spanning aa 1–621 of CP) of MAstV.
4. Discussion
Infection with gut viruses such as rotaviruses, AstV, and noroviruses (Norwalk virus, calicivirus)
are spread worldwide in human, animal, and bird species with a high seroprevalence [38–41]. Despite
remarkably growing studies on AstV epidemiology and molecular biology [41,42], little is known
about its immunogenicity and vaccine development. Recent findings about AstVs from different
species highlighted high seroprevalence [8,25,38,39], neurotropism [29,30], zoonotic transmission [26],
and huge economic losses [8,31,32,39]. These raise the importance of an efficient vaccine for this
infection, not only for the animal industry but also for public health concerns. Currently, there are no
vaccines or antiviral therapies against AstV diseases in either public health or animal health, which
persuaded us to research and to provide knowledge on vaccine design and immunization strategies
against AstVs. In several phylogenetic analysis studies, MAstV strains have been clustered to its
human counterpart [38,43]. Recent advanced sequence analyses have also identified two novel groups
of highly divergent AstVs, named MLB (Melbourne) and VA/HMO (Virginia/Human-Mink-Ovine-like)
in human individuals with diarrhea [44,45]. Furthermore, in clinical studies including the authors’
observations, there is evidence of MAstV-associated encephalitis and meningitis in minks and humans
raising the zoonotic emerging aspect of MAstV [26]. These studies highlight the importance of MAstV
vaccine research.
In this study, significantly higher anti-MAstV serum antibody detected in mice and mink showed
that CP truncates could elicit a reasonable systematic humoral immune response compared to full-length
CP. Humoral immunity plays an important role in protecting against AstVs since the presence of
protective antibodies against HAstV in healthy adults provides a mechanism of protection against
reinfection [46,47]. The development of anti-AstV therapies is hampered by the gap in knowledge of
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protective antibody epitopes on the AstV capsid surface [48] and the immunosuppressing peptides
along AstV CP [46,49,50]. Most of AstV vaccine research studies, including our previous study,
have been focused on the full-length CP vaccine candidates, which all showed partial unsatisfactory
immunity [36,37,51]. Our previous study, however, supports the feasibility of providing a truncated
AstV CP vaccine for protection against AstV infection [36]. The most recent trial was also relevant
to characterize a humoral immune response to a trivalent vaccine containing VP26 of the HAstV CP
immunization in mice [52].
Currently, there is no commercial immunological kit available to evaluate the cytokine levels
in mink to get a better overview of immune responses following administration of mink vaccine
candidates. Thus, we administered these MAstV vaccine candidates subcutaneously in adult NMRI
immunocompetent mice to evaluate both humoral and cellular Th1/Th2 cellular immune responses.
The MAstV CP truncates evaluated in this study could drastically induce higher IFN-γ secretion
in mice splenocytes compared to the full-length CP (Figure 4, Supplementary Figure S1D). This is
indicative of the role of full-length CP in depleting IFN-γ, type II interferon, a mechanism which is
exploited by AstV to promote viral replication in early infection. AstVs are IFN-sensitive viruses
that so far have been shown to induce IFN-β, type I interferon, which occurs late in infection and is
independent of replication [53]. This limits AstV infection and preserves barrier permeability in the
intestines [53,54]. Some other gut viruses such as rotavirus exploit IFN signaling in intestinal cells to
promote early viral replication [55,56]. Later on, IFN-induced apoptosis helps to control these viral
infections. Our findings show that truncation disrupts this antiviral suppression activity of AstV CP,
leading to better crosstalk between humoral and cellular immune responses.
Turkey AstV infection is a poor inducer of an adaptive immune response [57] and resulted in
reinfection. Studies using the newly emerging mouse model and clinical studies in humans also
demonstrated that the adaptive immune response is key in controlling AstV infection [58], which has
been shown not to be well induced by whole AstV or full-length CP [36,48]. A study by Bogdanoff, et al.
has revealed that the CP core domain (VP34) is antigenic in addition to the CP spike domains (VP27/29
and VP25/26) [47]. CP∆N truncate (aa 161–775) in this study, despite of lacking the N-terminus (aa
1–80) and partial inner core domain (aa 80–266) of CP, showed higher adaptive humoral and cellular
immune responses compared to CP and CP∆C. Previously, immune-suppressing mechanisms of a
peptide (aa 79–139) along N-terminus of AstV through interacting with a complement system has
been shown [49,50]. This supportive reason indicates that CP∆N also could not interrupt the crosstalk
between innate and adaptive immune responses due to the lack of suppression capability of the
complement system; therefore, it is the most immunogenic vaccine candidate in this study. Such
immunosuppressing mechanism ruled out by N-terminus peptide of CP∆C truncate (aa 1–621) may
likely be a reason for the lower cytokine induction in mice splenocytes, indicating a lesser capability of
this truncate to elicit adaptive immune responses after immunization, compared to the CP∆N truncate.
Notably, CP∆C also showed a higher cellular immune response after re-stimulating mice
splenocytes and higher humoral immune response in the mink model compared with full-length CP.
These results support a hypothesis that AstV CP has more mechanisms for immunosuppression than
the one for suppressing the complement system, which requires more investigation. Genomic [59] and
proteomic [49,60] studies have shown that conserved non-immunogenic regions are located at N- and
C-termini of CP. The innate immune system is the first line of defense against an invading pathogen.
Some mediators of innate immune systems such as active transforming growth factor beta (TGF-β)
levels and synthesis of inducible nitric oxide synthase (iNOS) protein are increased after AstV infection,
but the role of TGF-β after AstV infection is not known [38,61]. The presence of signal transducer and
activator of transcription 1 (STAT1) also decreases AstV replication with its mechanism remaining
unknown. Due to these innate immunosuppressing mechanisms of AstV, its infection is associated with
mild levels of histopathological signs, destruction of intestinal villi, and non-inflammatory diarrhea in
calves, lambs, and turkey case studies [62–65]. Our study also shows that AstV CP truncates could
stimulate some levels of secretion of IL-10 that is related to TGF-ß signaling. However, we were unable
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to measure secreted TGF-β in mice splenocytes after stimulation with full-length and the truncated
AstV CP immunogens. Taken together, research on finding extra immunosuppressing peptides along
AstV CP truncates and removing them from current CP truncates would indispensably benefit AstV
vaccinology by providing better crosstalk between innate and adaptive immune responses to elicit
even better adaptive immunity after vaccination.
Due to difficulties of litter vaccination, our ultimate goal of an MAstV vaccine is to provide
maternal passive immunity in litters by vaccinating adult female moms. Ideally, maternal passive
immunity observed among litters of mink refers to anti-AstV CP IgG that can pass to litters through
the placenta during gestation and/or through the milk after birth. The induction of humoral immunity
characterized by the stimulation of B-lymphocytes in moms is then critical in this work to generate
a protective level of anti-AstV IgG antibodies in newborn litters. The passive protection of mink
litters born to immunized moms after challenge with AstV -positive fecal filtrate was evaluated by the
investigation of clinical signs and virus shedding. Although the litters were challenged with a high
dose (107 genome copies) of a heterogeneous strain DK7627 which is known to be a causative agent of
shaking mink syndrome [28], the results indicated the presence of protective maternal anti-AstV IgG
antibodies in litters. Maternal passive immunization evaluated in the mink trial of this study supports
the application of such an immunization with a safe (gene- or protein-based) subunit AstV vaccine to
protect newborns after gestation. Maternal passive immunization has been used for vaccination against
other infections such as influenza virus [66,67], enterovirus [68,69], respiratory syncytial virus [70,71],
pertussis [72,73], group B streptococcus [74], tetanus [75,76], thereby showing that immunization during
pregnancy is the most effective means of preventing maternal and newborns mortality/morbidity.
Safety of vaccination in pregnancy, however, is a key consideration. Gene- and protein-based subunit
vaccines are classified among the safest types of vaccines and have always been considered for maternal
vaccination. These are effective strategies to prevent serious infections in mothers and their infants in
both veterinary and human medicine.
Truncated forms of MAstV CP could abate the virus shedding rate and clinical signs of AstV
infection in litters of immunized groups compared to the sham group. However, the AstV infection
could not be prevented completely by vaccination. The overdosing of virus inoculation of a heterologous
MAstV strain could be a reason for still observing virus shedding and diarrhea in some litters of the
vaccinated groups. Isolation and titration of AstVs have been difficult due to viral characteristics [77].
In the same way, our attempts to prepare a titrated infectious solution to be used for MAstV inoculation
failed. Lack of such a convenient infectious solution could overdose virus inoculation in mink litters,
leading to underestimating the protective efficacy of vaccines. Reduction in clinical signs showed
that maternal immunization produced effective neutralizing antibodies to protect litters against
MAstV infection.
The capacity to elicit an effective T- and B-lymphocyte immunity can be shown by the stimulation of
lymphocyte proliferation response, antibody titration, and cytokine profiling. In this work, we show that
truncated forms of AstV CP were the stronger inducers of antibody secretion and lymphoproliferation.
Increase of IL-2 and WST-1 tests showed a stronger ability of CP truncates to stimulate the proliferation
and differentiation of T cells, which is important for local and systematic humoral immunity [46].
Although no increase of cytokines was detected in splenocytes of the sham mice group, CP∆C and
CP∆N could elicit Th1 (IL-2 and IFN-γ), Th2 (IL-5), and Th2/T-reg (IL-10) in all immunized mice, with
the highest level of induction in the CP∆N-immunized group. It is well known that Th1-associated
cytokines help to regulate antiviral cellular responses, while Th2-associated cytokines enhance humoral
immune responses [38,46]. Subsequently, the level of serum neutralizing polyclonal antibodies also
significantly increased after the second immunization with both CP truncates. We showed that
CP truncates could better elicit adaptive humoral and cellular responses compared to full-length
CP. In contrast, immunization with MAstV CP raised a weak level of cytokines and antibodies in
mice, which is in accordance with previous field studies [36,37,51]. It is now well documented that
cooperation between cellular and humoral immunity is indispensable to provide a protective immune
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response against numerous pathogens [78], including AstVs [46,62]. Taken together, combined with
analyses of serum antibody levels, these data suggest that a better balanced Th1/Th2 immune response
is induced by the truncates of MAstV CP, compared to the suboptimal protection by full-length CP.
In this study, we did not collect intestine samples to measure the mucosal immune response that
may conceivably mediate protection against AstV infections. A previous study showed that CD4+
T cells that reside in the duodenal mucosa are presumably important in mucosal defense against
recurrent AstV infections [79]. Vaccine trials of CP of norovirus and rotaviruses in mice with similar
Th1/Th2 immune responses could elicit mucosal immunity [51,80,81]. Since local mucosal immunity is
believed to play an important role in protection against viral infections in the gastrointestinal tract,
an ideal vaccine would induce strong mucosal immunity [82]. Thus, further studies are required to find
out whether mucosal immune responses in the intestines could be elicited by vaccine administration
with CP truncates.
Due to the unavailability of MAstV challenge in mice, it remains unknown whether the immunity
evoked by subcutaneous MAstV CP immunization is capable of protecting against AstV infection.
However, we may anticipate that it would have a protective effect based on knowledge obtained from
studies of other similar viral infections like rotavirus and norovirus [51,80,81]. To date, young turkeys
(poults) infected with turkey AstV and mice (C57BL/6, IFNαR−/−) infected with murine AstV are the
best-defined animal models for AstV pathogenesis [54,62]. A 2016 study showed that wild type mice
infected with a fecal filtrate containing 2 × 107 genomic copies of murine AstV began shedding virus
within 2 days post-challenge, and viral titers reached a peak of 107 copies/µg RNA between 6 and
11 days post-challenge before decreasing over the remainder of the study, ultimately clearing by 53
days post-challenge [54]. Interestingly, this pattern of AstV shedding is so similar to our results for
mink litters (n = 16) of the sham group (Figure 6B). Almost no study has been reported on MAstV
pathogenesis and vaccine development. High genetic identity and clinical sign similarities between
mink and human AstVs could allow mink to be a worthy animal model for studying AstV immunology
and vaccine development. The results of this present study could provide us a new approach for
human AstV vaccine development.
5. Conclusions
We characterized humoral and cellular immune responses in a mouse model immunized with
not only AstV CP full-length but also AstV CP truncates as novel subunit vaccine candidates for
AstV infection. This study shows that lymphocytes T-helper cells provided help for effective humoral
immunity. Furthermore, we showed that optimal protection was given from maternal passive
neutralizing antibodies induced by two novel AstV subunit vaccines based on an N- and C-terminally
truncation strategy along AstV CP in a mink model. Further studies are required to distinguish the
immunosuppressing motifs from immunogenic epitopes and remove them from vaccine candidates,
thereby, leading to better adaptive immune responses. These conclusively support this idea that the
truncation strategy along AstV CP and passive immunization regime described in this study could
also be used to develop safe and effective subunit (proteomic or genomic) vaccine candidates not only
for animal health but also for human infants, elderlies, and immunocompromised populations.
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